{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:16:55Z","timestamp":1791605815479,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1-3","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031004","name":"KalVista Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long-term prophylaxis (LTP) has been shown to reduce the frequency of hereditary angioedema (HAE) attacks; however, attacks occurring in patients receiving LTP have not been well characterized. The objective of this systematic review was to evaluate the proportion of type I\/II HAE (HAE-C1INH) patients who experience attacks while receiving LTP, the characteristics of these attacks, and associated on-demand therapy use. A systematic search was conducted in PubMed to identify studies reporting LTP use with plasma-derived C1 inhibitor (pdC1INH), lanadelumab, berotralstat, androgens, or antifibrinolytics in patients with HAE-C1INH. Forty-five primary studies met the inclusion criteria. In phase 3 trials, attack-free rates were 40% for subcutaneous pdC1INH 60\u00a0IU\/kg twice weekly at 16\u00a0weeks, and 44% for lanadelumab 300\u00a0mg every second week at 6\u00a0months (77% during steady-state [days 70\u2013182]); there was no difference in attack-free rate for berotralstat 150\u00a0mg versus placebo at 24\u00a0weeks. Phase 3 studies reported a lower average attack severity with subcutaneous and intravenous pdC1INH versus placebo. With lanadelumab and berotralstat, the prophylactic treatment effect was more pronounced in peripheral attacks than in abdominal and laryngeal attacks. Laryngeal attacks accounted for 2%-7% of all attacks in observational and interventional studies, regardless of the LTP agent received. On-demand therapy was used in 49%-94% of attacks occurring in the presence of LTP. In conclusion, patients receiving LTP experienced attacks in all anatomic locations, including the larynx. Most attacks were treated with on-demand therapy, although outcomes were not reported. Access to on-demand therapy remains essential for all people with HAE-C1INH.<\/jats:p>","DOI":"10.1007\/s12016-024-09006-1","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T09:31:25Z","timestamp":1730971885000},"page":"83-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review"],"prefix":"10.1007","volume":"67","author":[{"given":"Hilary J.","family":"Longhurst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cancian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Grivcheva-Panovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Koleilat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Stobiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Yea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Audhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"9006_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E et al (2022) The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update. Allergy 77:1961\u20131990. https:\/\/doi.org\/10.1111\/all.15214","journal-title":"Allergy"},{"key":"9006_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Henry Li H, Lumry WR, Zuraw BL (2021) US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract 9:132\u201350.e3. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.046","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"9006_CR3","doi-asserted-by":"publisher","first-page":"952233","DOI":"10.3389\/falgy.2022.952233","volume":"12","author":"A Valerieva","year":"2022","unstructured":"Valerieva A, Longhurst HH (2022) Treatment of hereditary angioedema \u2013 single or multiple pathways to the rescue. Front Allergy 12(3):952233. https:\/\/doi.org\/10.3389\/falgy.2022.952233","journal-title":"Front Allergy"},{"key":"9006_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jaci.2021.05.016","volume":"148","author":"M Maurer","year":"2021","unstructured":"Maurer M, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Banerji A, Bernstein JA, Balle Boysen H, Busse PJ et al (2021) Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. J Allergy Clin Immunol 148:1526\u20131532. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.016","journal-title":"J Allergy Clin Immunol"},{"key":"9006_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","volume":"17","author":"K Bork","year":"2021","unstructured":"Bork K, Anderson JT, Caballero T, Craig T, Johnston DT, Li HH, Longhurst HJ, Radojici C, Riedl M (2021) Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol 17:40. https:\/\/doi.org\/10.1186\/s13223-021-00537-2","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"9006_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fmed.2018.00022","volume":"16","author":"WR Lumry","year":"2018","unstructured":"Lumry WR (2018) Hereditary angioedema: the economics of treatment of an orphan disease. Front Med (Lausanne) 16(5):22. https:\/\/doi.org\/10.3389\/fmed.2018.00022","journal-title":"Front Med (Lausanne)"},{"key":"9006_CR7","doi-asserted-by":"publisher","first-page":"CD013403","DOI":"10.1002\/14651858.CD013403.pub2","volume":"11","author":"N Beard","year":"2022","unstructured":"Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K (2022) Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev 11:CD013403. https:\/\/doi.org\/10.1002\/14651858.CD013403.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"9006_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL et al (2018) Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 320:2108\u20132121. https:\/\/doi.org\/10.1001\/jama.2018.16773","journal-title":"JAMA"},{"key":"9006_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","volume":"376","author":"H Longhurst","year":"2017","unstructured":"Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J et al (2017) Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med 376:1131\u20131140. https:\/\/doi.org\/10.1056\/NEJMoa1613627","journal-title":"N Engl J Med"},{"key":"9006_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","volume":"148","author":"B Zuraw","year":"2021","unstructured":"Zuraw B, Lumry WR, Johnston DT, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Banerji A, Bernstein JA et al (2021) Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol 148:164-172.e9. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.015","journal-title":"J Allergy Clin Immunol"},{"key":"9006_CR11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"9006_CR12","unstructured":"Wells GA, Shea B, O\u2019Connell D, Petersen J, Welch V, Losos M, Tugwell P (2021) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 03 December 2023."},{"key":"9006_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2500\/aap.2022.43.220016","volume":"43","author":"T Craig","year":"2022","unstructured":"Craig T, Feuersenger H, Pragst I, Dang J (2022) Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc 43:202\u2013208. https:\/\/doi.org\/10.2500\/aap.2022.43.220016","journal-title":"Allergy Asthma Proc"},{"key":"9006_CR14","doi-asserted-by":"publisher","first-page":"938.e1","DOI":"10.1016\/j.amjmed.2012.02.020","volume":"125","author":"BL Zuraw","year":"2012","unstructured":"Zuraw BL, Kalfus I (2012) Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 125:938.e1\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2012.02.020","journal-title":"Am J Med"},{"key":"9006_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/all.12658","volume":"70","author":"BL Zuraw","year":"2015","unstructured":"Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, Martinz-Saguer I, Rehman SMM, Staubach P, Feuersenger H, Parasrampuria R, Sidh J, Edelman J, Craig T (2015) Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy 70:1319\u20131328. https:\/\/doi.org\/10.1111\/all.12658","journal-title":"Allergy"},{"key":"9006_CR16","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1111\/all.14416","volume":"75","author":"MA Riedl","year":"2020","unstructured":"Riedl MA, Maurer M, Bernstein JA, Banerji A, Longhurst HJ, Li HH, Peng L, Hao J, Juethner S, Lumry WR, Investigators HELP (2020) Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy 75:2879\u20132887. https:\/\/doi.org\/10.1111\/all.14416","journal-title":"Allergy"},{"key":"9006_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H et al (2023) Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1079\u20131090. https:\/\/doi.org\/10.1016\/S0140-6736(23)00350-1","journal-title":"Lancet"},{"key":"9006_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1089\/ped.2020.1143","volume":"33","author":"D Levy","year":"2020","unstructured":"Levy D, Caballero T, Hussain I, Reshef A, Anderson J, Baker J, Schwartz LB, Cicardi M, Prusty S, Feuersenger H, Pragst I, Manning ME (2020) Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatr Allergy Immunol Pulmonol 33:136\u2013141. https:\/\/doi.org\/10.1089\/ped.2020.1143","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"9006_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.anai.2020.05.015","volume":"125","author":"JA Bernstein","year":"2020","unstructured":"Bernstein JA, Schwartz L, Yang W, Baker J, Anderson J, Farkas H, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Bygum A, Jacobs I, Feuersenger H, Pragst I, Riedl MA (2020) Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Ann Allergy Asthma Immunol 125:334-340.e1. https:\/\/doi.org\/10.1016\/j.anai.2020.05.015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9006_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.alit.2023.02.002","volume":"72","author":"T Fukuda","year":"2023","unstructured":"Fukuda T, Yamagami K, Kawahata K, Suzuki Y, Sasaki Y, Miyagi T, Jacobs I, Lawo J, Glassman F, Akama H, Hide M, Ohsawa I (2023) Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: results of a Phase 3 study. Allergol Int 72:451\u2013457. https:\/\/doi.org\/10.1016\/j.alit.2023.02.002","journal-title":"Allergol Int"},{"key":"9006_CR21","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jpeds.2012.11.030","volume":"162","author":"W Lumry","year":"2013","unstructured":"Lumry W, Manning ME, Hurewitz DS, Davis-Lorton M, Fitts D, Kalfus IN, Uknis ME (2013) Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 162:1017-1122.e1-2. https:\/\/doi.org\/10.1016\/j.jpeds.2012.11.030","journal-title":"J Pediatr"},{"key":"9006_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2500\/aap.2013.34.3645","volume":"34","author":"JW Baker","year":"2013","unstructured":"Baker JW, Craig TJ, Riedl MA, Banerji A, Fitts D, Kalfus IN, Uknis ME (2013) Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy Asthma Proc 34:162\u2013169. https:\/\/doi.org\/10.2500\/aap.2013.34.3645","journal-title":"Allergy Asthma Proc"},{"key":"9006_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/pai.13060","volume":"30","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2019","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Soteres DF, Nieto-Martinez SA, Christensen J, Jacobson KW, Moldovan D, Van Leerberghe A, Tang Y, Lu P, Vardi M, Schranz J, Martinez-Saguer I (2019) A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatr Allergy Immunol 30:553\u2013561. https:\/\/doi.org\/10.1111\/pai.13060","journal-title":"Pediatr Allergy Immunol"},{"key":"9006_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/all.15011","volume":"77","author":"A Banerji","year":"2022","unstructured":"Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, Martinez-Saguer I, Zanichelli A, Hao J, Inhaber N, Yu M, Riedl MA, Investigators HELP OLE (2022) Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy 77:979\u2013990. https:\/\/doi.org\/10.1111\/all.15011","journal-title":"Allergy"},{"key":"9006_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13223-021-00579-6","volume":"17","author":"A Iaboni","year":"2021","unstructured":"Iaboni A, Kanani A, Lacuesta G, Song C, Kan M, Betschel SD (2021) Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada. Allergy Asthma Clin Immunol 17:78. https:\/\/doi.org\/10.1186\/s13223-021-00579-6","journal-title":"Allergy Asthma Clin Immunol"},{"key":"9006_CR26","doi-asserted-by":"publisher","first-page":"100664","DOI":"10.1016\/j.waojou.2022.100664","volume":"15","author":"M Abuzakouk","year":"2022","unstructured":"Abuzakouk M, Ghorab O, Al-Hameli H, Salvo F, Grandon D, Maurer M (2022) Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience. World Allergy Organ J 15:100664. https:\/\/doi.org\/10.1016\/j.waojou.2022.100664","journal-title":"World Allergy Organ J"},{"key":"9006_CR27","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaip.2016.03.024","volume":"4","author":"BL Zuraw","year":"2016","unstructured":"Zuraw BL, Davis DK, Castaldo AJ, Christiansen SC (2016) Tolerability and effectiveness of 17-\u03b1-alkylated androgen therapy for hereditary angioedema: a re-examination. J Allergy Clin Immunol Pract 4:948-955.e15. https:\/\/doi.org\/10.1016\/j.jaip.2016.03.024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9006_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1684\/ejd\/2020.3758","volume":"30","author":"S Liu","year":"2020","unstructured":"Liu S, Xu Q, Xu Y, Wang X, Zhi Y (2020) Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey. Eur J Dermatol 30:169\u2013176. https:\/\/doi.org\/10.1684\/ejd\/2020.3758","journal-title":"Eur J Dermatol"},{"key":"9006_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","volume":"100","author":"K Bork","year":"2008","unstructured":"Bork K, Bygum A, Hardt J (2008) Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 100:153\u2013161. https:\/\/doi.org\/10.1016\/S1081-1206(10)60424-3","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9006_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-016-0423-1","volume":"11","author":"UC Steiner","year":"2016","unstructured":"Steiner UC, Weber-Chrysochoou C, Helbling A, Scherer K, Grendelmeier PS, Wuillemin WA (2016) Hereditary angioedema due to C1 - inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study. Orphanet J Rare Dis 11:43. https:\/\/doi.org\/10.1186\/s13023-016-0423-1","journal-title":"Orphanet J Rare Dis"},{"key":"9006_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/cei.12379","volume":"178","author":"C Wintenberger","year":"2014","unstructured":"Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, Martin L, Gompel A, Bouillet L (2014) Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 178:112\u2013117. https:\/\/doi.org\/10.1111\/cei.12379","journal-title":"Clin Exp Immunol"},{"key":"9006_CR32","unstructured":"Takeda Manufacturing Austria AG (2022) Cinryze 500 IU powder and solvent for solution for injection. Takeda Manufacturing AG, Vienna, Austria"},{"key":"9006_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1716995","volume":"379","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Bygum A, Grivcheva-Panovska V, Magerl M, Graff J, Steiner UC et al (2018) Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N Engl J Med 379:352\u2013362. https:\/\/doi.org\/10.1056\/NEJMoa1716995","journal-title":"N Engl J Med"},{"key":"9006_CR34","doi-asserted-by":"publisher","first-page":"e12035","DOI":"10.1002\/clt2.12035","volume":"11","author":"H Farkas","year":"2021","unstructured":"Farkas H, Stobiecki M, Peter J, Kinaciyan T, Maurer M, Ayg\u00f6ren-P\u00fcrs\u00fcn E et al (2021) Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin Transl Allergy 11:e12035. https:\/\/doi.org\/10.1002\/clt2.12035","journal-title":"Clin Transl Allergy"},{"key":"9006_CR35","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.jaip.2021.03.057","volume":"9","author":"HJ Wedner","year":"2021","unstructured":"Wedner HJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Bernstein J, Craig T, Gower R, Jacobs JS, Johnston DT, Lumry WR, Zuraw BL, Best JM, Iocca HA, Murray SC, Desai B, Nagy E, Sheridan WP, Kiani-Alikhan S (2021) Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). J Allergy Clin Immunol Pract 9:2305-2314.e4. https:\/\/doi.org\/10.1016\/j.jaip.2021.03.057","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9006_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13223-017-0203-z","volume":"13","author":"W Aberer","year":"2017","unstructured":"Aberer W, Maurer M, Bouillet L, Zanicheeli A, Caballero T, Longhurst HJ, Perrin A, Andresen I, IOS Study Group (2017) Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Allergy Asthma Clin Immunol 13:31. https:\/\/doi.org\/10.1186\/s13223-017-0203-z","journal-title":"Allergy Asthma Clin Immunol"},{"key":"9006_CR37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.anai.2016.03.008","volume":"116","author":"ER Rasmussen","year":"2016","unstructured":"Rasmussen ER, Aagaard L, Bygum A (2016) Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: effectiveness and cost. Ann Allergy Asthma Immunol 116:476\u2013477. https:\/\/doi.org\/10.1016\/j.anai.2016.03.008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9006_CR38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/archinte.163.10.1229","volume":"163","author":"K Bork","year":"2003","unstructured":"Bork K, Hardt J, Schicketanz KH, Ressel N (2003) Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229\u20131235. https:\/\/doi.org\/10.1001\/archinte.163.10.1229","journal-title":"Arch Intern Med"},{"key":"9006_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2362.2010.02402.x","volume":"41","author":"G F\u00fcst","year":"2011","unstructured":"F\u00fcst G, Farkas H, Csuka D, Varga L, Bork K (2011) Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 41:256\u2013262. https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02402.x","journal-title":"Eur J Clin Invest"},{"key":"9006_CR40","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/cea.14182","volume":"52","author":"R Hakl","year":"2022","unstructured":"Hakl R, Kukl\u00ednek P, Sobotkov\u00e1 M, Kr\u010dmov\u00e1 I, Kr\u00e1l\u00ed\u010dov\u00e1 P, Vachov\u00e1 M, Hanzl\u00edkov\u00e1 J, Nov\u00e1\u010dkov\u00e1 M, Svoboda M, Kov\u00e1\u010dov\u00e1 I, Litzman J (2022) Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema. Clin Exp Allergy 52:994\u2013997. https:\/\/doi.org\/10.1111\/cea.14182","journal-title":"Clin Exp Allergy"},{"key":"9006_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13223-019-0362-1","volume":"15","author":"HH Li","year":"2019","unstructured":"Li HH, Zuraw B, Longhurst HJ, Cicardi M, Bork K, Baker J et al (2019) Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. Allergy Asthma Clin Immunol 15:49. https:\/\/doi.org\/10.1186\/s13223-019-0362-1","journal-title":"Allergy Asthma Clin Immunol"},{"key":"9006_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/MEJMoa0805538","volume":"363","author":"BL Zuraw","year":"2010","unstructured":"Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513\u2013522. https:\/\/doi.org\/10.1056\/MEJMoa0805538","journal-title":"N Engl J Med"},{"key":"9006_CR43","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","volume":"7","author":"T Craig","year":"2019","unstructured":"Craig T, Zuraw B, Longhurst H, Circardi M, Bork K, Grattan C et al (2019) Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract 7:1793-1802.e2. https:\/\/doi.org\/10.1016\/j.jaip.2019.01.054","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9006_CR44","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.jaip.2019.01.007","volume":"7","author":"T Craig","year":"2019","unstructured":"Craig T, Lumry W, Cicardi M, Zuraw B, Bernstein JA, Anderson J et al (2019) Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. J Allergy Clin Immunol Pract 7:2035\u20132038. https:\/\/doi.org\/10.1016\/j.jaip.2019.01.007","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9006_CR45","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/all.15620","volume":"78","author":"AD Dorr","year":"2023","unstructured":"Dorr AD, Chopra C, Coulter TI, Dempster J, Dziadzio M, El-Shanawany T et al (2023) Lanadelumab for the prevention of hereditary angioedema attacks: a real-world UK audit. Allergy 78:1369\u20131371. https:\/\/doi.org\/10.1111\/all.15620","journal-title":"Allergy"},{"key":"9006_CR46","doi-asserted-by":"publisher","first-page":"978","DOI":"10.36849\/JDD.2020.5269","volume":"19","author":"J Hahn","year":"2020","unstructured":"Hahn J, Trainotti S, Wigand MC, Schuler PJ, Hoffmann TK, Greve J (2020) Prospective analysis in patients with HAE under prophylaxis with lanadelumab: a real-life experience. J Drugs Dermatol 19:978\u2013983. https:\/\/doi.org\/10.36849\/JDD.2020.5269","journal-title":"J Drugs Dermatol"},{"key":"9006_CR47","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/all.15641","volume":"78","author":"M Ahuja","year":"2023","unstructured":"Ahuja M, Dorr A, Bode E, Boulton APR, Buckland M, Chee S et al (2023) Berotralstat for the prophylaxis of hereditary angioedema-real-world evidence data from the United Kingdom. Allergy 78:1380\u20131383. https:\/\/doi.org\/10.1111\/all.15641","journal-title":"Allergy"},{"key":"9006_CR48","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.jaip.2023.02.037","volume":"11","author":"CH Katelaris","year":"2023","unstructured":"Katelaris CH, Boicos K, Button PH, McCloud PI, Burton PK, Perram FA, Youssef S, Tognarini D (2023) Living with hereditary angioedema in Australia: findings from a national observational study using short message service to monitor the burden of disease. J Allergy Clin Immunol Pract 11:2457\u201367.e1. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.037","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9006_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1398-9995.2010.02433.x","volume":"66","author":"A Zanichelli","year":"2011","unstructured":"Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M (2011) Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 66:192\u2013196. https:\/\/doi.org\/10.1111\/j.1398-9995.2010.02433.x","journal-title":"Allergy"},{"key":"9006_CR50","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","volume":"376","author":"A Banerji","year":"2017","unstructured":"Banerji A, Busse P, Shennak M, Lumry W, Davis-Lorton M, Wedner HJ et al (2017) Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med 376:717\u2013728. https:\/\/doi.org\/10.1056\/NEJMoa1605767","journal-title":"N Engl J Med"},{"key":"9006_CR51","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","volume":"386","author":"LM Fijen","year":"2022","unstructured":"Fijen LM, Riedl MA, Bordone L, Bernstein JA, Raasch J, Tachdjian R, Craig T, Lumry WR, Manning ME, Alexander VJ, Newman KB, Revenko A, Baker BF, Nanavati C, Macleod AR, Schneider E, Cohn DM (2022) Inhibition of prekallikrein for hereditary angioedema. N Engl J Med 386:1026\u20131133. https:\/\/doi.org\/10.1056\/NEJMoa2109329","journal-title":"N Engl J Med"},{"key":"9006_CR52","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jaip.2022.04.030","volume":"10","author":"FG Minafra","year":"2022","unstructured":"Minafra FG, Cunha LAO, Mariano RGS, Goebel GA, de Lima LS, Pinto JA (2022) Investigation of mortality of hereditary angioedema in a reference center in Brazil. J Allergy Clin Immunol Pract 10:1805\u20131812. https:\/\/doi.org\/10.1016\/j.jaip.2022.04.030","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9006_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13023-018-0922-3","volume":"13","author":"MA Riedl","year":"2018","unstructured":"Riedl MA, Banerji A, Manning ME, Burrell E, Joshi N, Patel D, Machnig T, Tai M, Watson DJ (2018) Treatment patterns and healthcare resource utilization among patients with hereditary angioedma in the United States. Orphanet J Rare Dis 13:180. https:\/\/doi.org\/10.1186\/s13023-018-0922-3","journal-title":"Orphanet J Rare Dis"},{"key":"9006_CR54","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/all.15962","volume":"79","author":"RS Petersen","year":"2024","unstructured":"Petersen RS, Fijen LM, Cohn DM (2024) Efficacy outcomes in trials with prophylactic hereditary angioedema therapy: A systematic review. Allergy 79:1345\u20131348. https:\/\/doi.org\/10.1111\/all.15962","journal-title":"Allergy"},{"key":"9006_CR55","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jaip.2024.04.007","volume":"12","author":"RS Peterson","year":"2024","unstructured":"Peterson RS, Fijen LM, Apfelbacher C, Magerl M, Weller K, Aberer W (2024) A core outcome set for efficacy of acute treatment of hereditary angioedema. J Allergy Clin Immunol Pract 12:1614\u20131621. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.007","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-024-09006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-024-09006-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-024-09006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:25:08Z","timestamp":1734009908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-024-09006-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":55,"journal-issue":{"issue":"1-3","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9006"],"URL":"https:\/\/doi.org\/10.1007\/s12016-024-09006-1","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"12 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for this literature review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"H. J. Longhurst has received grants or contracts from CSL Behring, Intellia, and KalVista, consulting fees from CSL Behring, Intellia, KalVista, and Takeda, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from CSL Behring and Takeda, support for travel and\/or attending meetings from CSL Behring, Intellia, KalVista, Pharming, and Takeda, has participated on a Data Safety Monitoring Board or Advisory Board for CSL Behring, Intellia, KalVista, and Takeda, has received equipment, materials, drugs, medical writing, gifts or other services from CSL Behring, Intellia, KalVista, and has held a leadership or fiduciary role in HAE International Scientific Steering Committees. L. Bouillet has received support for the medical writing of this manuscript which was funded by KalVista, has received consulting fees from Takeda, CSL Behring, BioCryst, and KalVista, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Takeda and BioCryst, payment for expert testimony from Takeda, CSL Behring, Pharvaris, BioCryst, and KalVista, support for travel and\/or attending meetings from Takeda and BioCryst, has participated on a Data Safety Monitoring Board or Advisory Board for Takeda, BioCryst, CSL Behring, KalVista, and Pharvaris, and is the vice-president of the Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). M. Cancian has received consulting fees from CSL Behring, Takeda, Pharvaris, KalVista, and BioCryst, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from KalVista, Takeda, and CSL Behring, and support for travel and\/or attending meetings from CSL Behring and Takeda. V. Grivcheva-Panovska has received support for the medical writing of this manuscript which was funded by KalVista, consulting fees from Pharming NV, KalVista, Astria, and Takeda, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Pharming NV, Takeda, BioCryst, and KalVista, travel grants from Pharming NV and Takeda, has participated on a Data Safety Monitoring Board or Advisory Board for Pharming NV, KalVista, Takeda, and Astria and has received medical writing assistance from Pharming NV, BioCryst, and KalVista. M Koleilat has received support for the medical writing of this manuscript which was funded by KalVista, and has received grants or contracts as a clinical trial site from KalVista. M. Magerl has received support for medical writing of this manuscript which was funded by KalVista, research funding as a study center investigator from KalVista, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from CSL Behring, Shire\/Takeda, Pharming Technologies, BioCryst, Novartis, Octapharma, KalVista, Intellia, and Pharvaris. S. Savic has received support for the present manuscript from KalVista, grants or contracts from Novartis, SOBI, and CSL Behring, consulting fees from Novartis, SOBI, CSL Behring, Takeda, KalVista, BioCryst, Pharming, Celdex, and AstraZeneca, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Takeda, SOBI, Novartis, and KalVista, has received support for travel and\/or attending meetings from Novartis, and has a leadership or fiduciary role for the British Society for Immunology. M. Stobiecki has received lecture and presentations honoraria and consulting fees from CSL Behring, Takeda\/Shire, and BioCryst. R Tachdjian has received grants or contracts from Astria, Ionis, CSL Behring, BioCryst, Takeda, KalVista, and Pharvaris, consulting fees from BioCryst, CSL Behring, Pharming, Takeda, KalVista, and Ionis, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from BioCryst, CSL Behring, Pharming, Takeda, Ionis, Sanofi, Regeneron, AstraZeneca, and GlaxoSmithKline, and has participated on a Data Safety Monitoring Board or Advisory Board for Astria, BioCryst, CSL Behring, KalVista, Pharming, Takeda, and Ionis. B. Healy is an employee of ApotheCom, which received funding from KalVista Pharmaceuticals for the project and support for travel and\/or meeting attendance from KalVista Pharmaceuticals. C. M. Yea and P. K. Audhya hold stock or stock options and are employees of KalVista Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}